Market closed
Lyell Immunopharma/$LYEL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lyell Immunopharma
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Ticker
$LYEL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
300
Website
LYEL Metrics
BasicAdvanced
$129M
-
-$1.31
-0.27
-
Price and volume
Market cap
$129M
Beta
-0.27
52-week high
$2.88
52-week low
$0.39
Average daily volume
806K
Financial strength
Current ratio
7.057
Quick ratio
6.889
Long term debt to equity
13.32
Total debt to equity
15.403
Management effectiveness
Return on assets (TTM)
-22.05%
Return on equity (TTM)
-66.10%
Valuation
Price to revenue (TTM)
1,878.541
Price to book
0.34
Price to tangible book (TTM)
0.34
Price to free cash flow (TTM)
-0.703
Growth
Revenue change (TTM)
-53.08%
Earnings per share change (TTM)
40.32%
3-year revenue growth (CAGR)
-82.11%
3-year earnings per share growth (CAGR)
-10.68%
What the Analysts think about LYEL
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Lyell Immunopharma stock.
LYEL Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
LYEL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
LYEL News
AllArticlesVideos
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
GlobeNewsWire·1 week ago
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024
GlobeNewsWire·1 month ago
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Lyell Immunopharma stock?
Lyell Immunopharma (LYEL) has a market cap of $129M as of April 23, 2025.
What is the P/E ratio for Lyell Immunopharma stock?
The price to earnings (P/E) ratio for Lyell Immunopharma (LYEL) stock is 0 as of April 23, 2025.
Does Lyell Immunopharma stock pay dividends?
No, Lyell Immunopharma (LYEL) stock does not pay dividends to its shareholders as of April 23, 2025.
When is the next Lyell Immunopharma dividend payment date?
Lyell Immunopharma (LYEL) stock does not pay dividends to its shareholders.
What is the beta indicator for Lyell Immunopharma?
Lyell Immunopharma (LYEL) has a beta rating of -0.27. This means that it has an inverse relation to market volatility.